GlassScriptPhysician profile
Erin Thompson
NPI 1205384872
$2,735.38
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $626 · 2022: $765 · 2023: $700 · 2024: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305 · Education: $39.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.96 |
| Education | $39.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $650.21 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $420.63 | 2021-2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $336.32 | 2021-2022 | |
| Axsome Therapeutics, INC. | $180.49 | 2022-2024 | Auvelity |
| Corium, LLC | $157.91 | 2022-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $155.28 | 2021-2023 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $154.76 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $145.24 | 2021-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $105.10 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $89.44 | 2023-2024 | Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $74.73 | 2023-2024 | Qelbree, Qelbree |
| Lundbeck LLC | $74.14 | 2021-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $59.36 | 2022-2024 | Hetlioz, Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $43.11 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $18.04 | 2023 | Jornay Pm |
| Xeris Pharmaceuticals, INC. | $17.99 | 2024 | Gvoke Hypopen |
| Novo Nordisk INC | $12.83 | 2023 | Ozempic, Rybelsus |
| Indivior INC. | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.